Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed bag of new hires, sideways moves, and departures. The headline news is that ...

Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Bristol-Myers Squibb (BMS) reported stronger-than-expected earnings for the fourth quarter of 2025, with earnings per share (EPS) reaching $1.26, surpassing the anticipated $1.12. Revenue also ...

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. The hunt for blockbuster drugs has sent ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today reported fourth quarter and full-year 2025 financial results. Visit the company’s Investor ...

CEO Christopher Boerner opened by highlighting, “2025 was a year of focused execution across the business. We believe our results further demonstrate the ongoing strength in our growth portfolio as we ...

Robert Burakoff, MD, MPH, is a board-certified gastroenterologist who serves as vice chair of Ambulatory Services at Lower Manhattan Hospital and professor of medicine at the Weill Cornell Medical ...

BMS achieved non-GAAP EPS of $6.15 for the full year, a substantial improvement from $1.15 in 2024. Credit: Piotr Swat / Shutterstock.com. Bristol Myers Squibb (BMS) has reported full-year 2025 ...

Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy continues to struggle with uptake. Bristol Myers Squibb sales hit $12.5 ...